6268-18-4

Upstream product

• 2159-38-8 2-(3'-nitrobenzoyl)benzoic acid 
• 85-52-9 2-Benzoylbenzoic acid 

Downstream Products

• 116289-88-4 2-(3-amino-benzoyl)-benzoic acid ethyl ester 
• 634602-13-4 2-(3-hydroxy-benzoyl)-benzoic acid 
• 82-45-1 1-amino-9,10-anthracenedione 
• 117-79-3 2-aminoanthraquinone 
• 13450-37-8 o-(3-chloro-benzoyl)-benzoic acid 
• 13450-06-1 9b-(3-chloro-phenyl)-1,2,3,9b-tetrahydro-imidazo[2,1-a]isoindol-5-one 
• 857042-95-6 C₁₆H₁₄N₂O₂ 
• 605-32-3 2-hydroxy-9,10-anthraquinone 

Relevant academic research and scientific papers

The discovery of 1,2,3,9b-tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 1

Respiratory syncytial virus (RSV) is a major cause of respiratory tract infections in infants, young children and adults. Compound 1a (9b-(4-chlorophenyl)-1-(4-fluorobenzoyl)-1,2,3,9b-tetrahydro-5H-imidazo[2,1-a]isoindol-5-one) was identified as an inhibitor of A and B strains of RSV targeting the fusion glycoprotein. SAR was developed by systematic exploration of the phenyl (R1) and benzoyl (R2) groups. Furthermore, introduction of a nitrogen at the 8-position of the tricyclic core resulted in active analogues with improved properties (aqueous solubility, protein binding and log D) and excellent rat pharmacokinetics (e.g., rat oral bioavailability of 89% for compound 17).